The Voice of Rheumatology (VOR) Coalition convened last month at ACR Convergence 2024 in Washington, D.C., to discuss the pressing federal and state legislative priorities…
Latest News
Billing and Coding Updates for G2211 in 2025
On Nov. 1, the Centers for Medicare & Medicaid Services finalized its proposal for an incremental expansion of the G2211 add-on code for complexity.
What Providers & Patients Should Know About Medicare Benefit Changes in 2025
Changes to Medicare benefits in 2025 include an annual $2,000 cap on out-of-pocket costs for covered Part D drugs and a new, voluntary Medicare Prescription Payment Plan intended to help beneficiaries manage drug costs.
Telemedicine Flexibilities for Controlled Substance Prescriptions Extended Through 2025
A third extension of telemedicine flexibilities will continue to allow prescription of controlled substances via telemedicine without an in-person visit through the end of 2025.
2024 Rheumatology Fellowship Match Day Results
Match Day Results Highlight Continued Interest in Adult Rheumatology & Sharp Declines in Pediatric Rheumatology The ACR applauds another successful recruitment season for rheumatology and…
Prevalence of Fibromyalgia & Widespread Pain in Psoriatic Arthritis: Association with Disease Severity Assessment in a Large U.S. Registry
According to a new study, fibromyalgia prevalence is elevated in PsA and is associated with elevated disease measures, confounding reliable disease assessment for treat-to-target goals.
B Cell-Depleting Therapy in SLE
“SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”
How to Write an Effective Fellowship Application Essay
I read a lot of essays and, believe it or not, I’ve been known to write a few on occasion as well. The majority of…
Anti-Infliximab Antibodies Predict Response in Axial Spondyloarthritis
Pimentel et al. evaluated the influence of anti-infliximab antibodies on patients with axial spondyloarthritis. The researchers found that anti-infliximab antibodies were associated with decreased infliximab performance and difficulty tapering its dosage, as well as a good clinical response to a second, alternate tumor necrosis factor inhibitor.